A novel botulinum neurotoxin, previously reported as Serotype H, has a hybrid-like structure with regions of similarity to the structures of serotypes A and F and is neutralized with Serotype A antitoxin

Journal of Infectious Diseases

Volumn 213, Issue 3, 2016, Pages 379-385

  Maslanka, Susan E ^a   Lúquez, Carolina ^a   Dykes, Janet K ^a   Tepp, William H ^b   Pier, Christina L ^b   Pellett, Sabine ^b   Raphael, Brian H ^a   Kalb, Suzanne R ^a   Barr, John R ^a   Rao, Agam ^a   Johnson, Eric A ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

botulinum toxin; botulism; Clostridium botulinum; neuronal cell based assay; neutralization; serotype

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN F;

ARTICLE; BACTERIAL STRAIN; BOTULISM; CONTROLLED STUDY; DNA SEQUENCE; GENE STRUCTURE; GENETIC ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; SEROTYPE; ANIMAL; BIOASSAY; CHEMISTRY; CLASSIFICATION; HUMAN; MOUSE;

ANIMALS; BIOLOGICAL ASSAY; BOTULINUM ANTITOXIN; BOTULINUM TOXINS; HUMANS; MICE;

EID: 84960350022     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv327     Document Type: Article

References (43)

1. Yu PA, Maslanka SE, St Louis ME, Swerdlow DL. Botulism. In: Abrutyn E, Brachman PS, eds. Bacterial infections in humans. New York: Springer, 2009: 159-76.
2. CDC. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational Botulinum antitoxin E. MMWR Morb Mortal Wkly Rep 2010; 59: 299.
3. FDA approves first Botulism Antitoxin for use in neutralizing all seven known botulinum nerve toxin serotypes [news release]. 2013. http: //www.fda.gov/news Events/Newsroom/Press/Announcements/ucm345128.htm. Accessed 12 April 2014.
4. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. New Eng J Med 2005; 354: 462-71.
5. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: A clinical and epidemiologic review. Annals of Internal Med 1998; 123: 221-8.
6. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984; 76: 794-8.
7. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nature 2014; 12: 535-49.
8. Arndt JW, Jacobson MJ, Abola EE,. et al. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol 2006; 362: 733-42.
9. Hill KK, Smith TJ, Helma CH,. et al. Genetic diversity among botulinum neurotoxin-producing clostridial strains. J Bacteriol 2007; 189: 818-32.
10. Moriishi K, Koura M, Abe N,. et al. Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms. Biochimica et Biophysica Acta 1996; 1307: 123-6.
11. Nakamura K, Kohda T, Umeda K, Yamamoto H, Mukamoto M, Kosaki S. Characterization of the D/C mosaic neurotoxin produced by Clostridium botulinum associated with bovine botulism in Japan. Vet Microbiol 2010; 140: 147-54.
12. Raphael BH, Choudoir MJ, Lúquez C, Fernández R, Maslanka SE. Sequence diversity of genes encoding botulinum neurotoxin type F. Appl Environ Microbiol 2010; 76: 4805-12.
13. Kalb SR, Baudys J, Smith TJ, Smith LA, Barr JR. Three enzymatically active neurotoxins of Clostridium botulinum strain Af84; BoNT/A2, /F4, and /F5. Anal Chem 2014; 86: 3254-62.
14. Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 2013; 209: 183-91.
15. Johnson EA. Validity of botulinum neurotoxin serotype H. J Infect Dis 2014; 210: 992-3.
16. Gonzalez-Escalona N, Thirunavukkarasu N, Singh A,. et al. Draft genome sequence of bivalent Clostridum botulinum strain IBCA10-7060, encoding botulinum neurotoxin B and a new FA mosaic type. Genome Announcements 2014; 2: e01275-14.
17. Lole KS, Bollinger RC, Paranjape RS,. et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73: 152-60.
18. Maslanka SE, Solomon HM, Sharma S, Johnson EA. Clostridium botulinum and its toxins. In: Tortorello ML, Downes FP, Doores S, Ito K, Salfinger Y, eds. Compendium of methods for the microbiological examination of foods. Washington, DC: American Public Health Association, 2013.
19. Reed LJ, Muench H. A simple method for estimating fifty percent end points. Am J Hyg 1938; 27: 493-7.
20. Hatheway CL. Botulism. In: Balows A, Hausler WJ Jr, Ohashi M, Turano A, eds. Laboratory diagnosis of infectious diseases: principles and practice. Vol 1. Berlin: Springer-Verlag, 1988: 111-33.
21. Malizio CJ, Goodnough MC, Johnson EA. Purification of Clostridium botulinum type A neurotoxin. In: Holst O, ed. Bacterial toxins: methods and protocols, methods in molecular biology. Vol 145. Totowa, NJ: Humana Press, 2000: 27-39.
22. Wang D, Baudys J, Krilich JC, Smith TJ, Barr JR, Kalb SR. A two-stage multiplex method for quantitative analysis of botulinum neurotoxin type A, B, E, and F by MALDI-TOF mass spectrometry. Anal Chem 2014; 86: 10847-54.
23. Whitemarsh RC, Strathman MJ, Chase LG,. et al. Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol Sci 2012; 126: 426-35.
24. Pellett S, Tepp WH, Clancy CM, Borodic GE, Johnson EA. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett 2007; 581: 4803-8.
25. Pellett S, Tepp WH, Toth SI, Johnson EA. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J Pharmacol Toxicol Methods 2010; 61: 304-10.
26. Smith TJ, Hill KK, Raphael BH. Historical and current perspectives on Clostridium botulinum diversity. Res Microbiol 2014; 166: 290-302.
27. Hatheway CL, McCroskey LM, Lombard GL, Dowell VR Jr. Atypical toxin variant of Clostridium botulinum type B associated with infant botulism. J Clin Microbiol 1981; 14: 607-11.
28. Giménez DF. Clostridium botulinum subtype Ba. Zbl Bakt Hyg A 1984; 257: 68-72.
29. Dover N, Barash JR, Hill KK, Xie G, Arnon SS. Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis 2013; 209: 192-202.
30. Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol 2007; 365: 196-210.
31. Webb RP, Smith LA. What next for botulism vaccine development? Expert Rev Vaccines 2013; 12: 481-92.
32. Przedpelski A, Tepp WH, Kroken AR,. et al. Enhancing the protective immune response against botulism. Infect Immun 2013; 81: 2638-44.
33. Burke GS. Notes on Bacillus botulinus. J Bacteriol 1919; 4: 555-71.
34. Bowmer EJ. Preparation and assay of the International standards for Clostridium botulinum types A, B, C, D, and E antitoxins. Bull World Health Organ 1963; 29: 701-9.
35. Jones RGA, Corbel MJ, Sesardic D. A review of WHO International standards for botulinum antitoxins. Biologicals 2006; 34: 223-6.
36. Giménez DF, Ciccarelli AS. Variaciones antigenicas en toxinas botulinicas del tipo F. Ensayo De definiciones para la tipificacion serologica y clasificacion De Clostridium botulinum. Medicina (Bs Aires) 1972; 32: 596-606.
37. Giménez DF, Giménez JA. Serological subtypes of botulinal neurotoxins. In: Das-Gupta BR, ed. Botulinum and tetanus neurotoxins. New York: Plenus Press, 1993: 421-30.
38. Smith TJ, Lou J, Geren IN,. et al. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 2005; 73: 5450-7.
39. Kalb SR, Lou J, Garcia-Rodriguez C,. et al. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One 2009; 4: e5355.
40. Kalb SR, Baudys J, Raphael BH,. et al. Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A). Anal Chem 2015; 87: 3911-7.
41. Bengtson IA. Standardization of botulism antitoxins. Amer J Pub Health 1921; 11: 352-7.
42. Sesardic D, Leung T, Gaines Das R. Role of standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals 2003; 31: 265-76.
43. Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 1984; 150: 407-12.